Key result
Triple lipid-lowering therapy reduces LDL-C by ~21% in pediatric HoFH but fails therapeutic targets.
Why the study?
Homozygous familial hypercholesterolemia is a rare hereditary disorder with a particularly severe clinical course and extremely challenging treatment.
Does triple combination therapy with atorvastatin, ezetimibe, and evolocumab reduce LDL-C levels and promote xanthoma regression in a pediatric patient with homozygous familial hypercholesterolemia due to compound heterozygous LDLR variants?
Case Report (n=1)
Does triple combination therapy with atorvastatin, ezetimibe, and evolocumab reduce LDL-C levels and promote xanthoma regression in a pediatric patient with homozygous familial hypercholesterolemia due to compound heterozygous LDLR variants?
In a pediatric patient with homozygous familial hypercholesterolemia and severe LDLR defects, conventional triple therapy (atorvastatin, ezetimibe, evolocumab) achieved only modest LDL-C reduction without reaching therapeutic targets or resolving xanthomas, highlighting the need for early initiation of LDLR-independent therapies or LDL apheresis.
Answers are grounded in this paper and cite their sources.
Triple therapy yielded only modest LDL-C reduction without targets met in this pediatric HoFH case; leaves open the need for LDLR-independent agents.
Familial hypercholesterolemia (FH) is a hereditary disorder primarily due to variants of low-density lipoprotein receptor (LDLR) gene, characterized by markedly elevated plasma low-density lipoprotein cholesterol (LDL-C) levels and a severely increased risk of premature atherosclerotic cardiovascular disease (ASCVD). For rare homozygous FH (HoFH), the condition is particularly severe and the treatment is extremely challenging. This case described a pediatric HoFH patient presenting with multiple xanthomas and a LDL-C level of 17.95 mmol/L (694.04 mg/dL). Genetic testing further revealed compound heterozygous variants in the LDLR gene: a missense variant (NM_000527.5:c.298G>A) and a classic splicing variant (NM_000527.5:c.817+1G>A), confirming the diagnosis of biallelic semidominant hypercholesterolemia, monogenic (same gene, different variants). The patient received triple combination therapy with atorvastatin, ezetimibe and evolocumab, and actively improved his lifestyle. After nearly two years of follow-up, his LDL-C levels decreased from baseline to 14.23 mmol/L (550.59 mg/dL). However, this failed to reach the therapeutic goal and cutaneous xanthomas at the joints showed no significant regression. For such patients with severe defects in LDLR function, agents independent of LDLR pathway, LDL apheresis, or even liver transplantation should be initiated early to improve long-term prognosis. This report underscores the role of prioritizing phenotypic identification, targeted genetic testing, strengthening medical cooperation and maximizing local advantages in optimizing the management of HoFH especially within resource constraints, advocating for the establishment of a fast-track path for approval and supervision of new drugs for HoFH covered by official medical subsidies and LDL apheresis centers specialized for children in China.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted a case report in Homozygous familial hypercholesterolemia (compound heterozygous LDLR variants) with multiple xanthomas (n=1). Triple combination therapy with atorvastatin, ezetimibe, and evolocumab plus lifestyle improvement was evaluated on LDL-C level and regression of cutaneous xanthomas. Triple therapy with atorvastatin, ezetimibe, and evolocumab reduced LDL-C from 17.95 to 14.23 mmol/L over nearly 2 years in a pediatric HoFH case, failing to reach therapeutic goals.
Synapse has enriched 10 related papers. Consider them for comparative context: